News

New exon‑51 skipping therapy boosts dystrophin and patient strength, with upcoming trial readouts aiming to support accelerated FDA approval.

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed the unique role of nurses in neurology, from their perspective working with patients with MS.

FACT, an ongoing trial, evaluates the efficacy of efgartigimod alfa injection versus high-dose intravenous methylprednisolone in a cohort patients with neuromyelitis optica spectrum disorder.

Preliminary phase 1a findings suggest the investigational tau aggregation inhibitor OLX-07010 demonstrated favorable safety and pharmacokinetic profiles in healthy volunteers, supporting continued development in Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Amlenetug, a monoclonal antibody targeting aggregated α-synuclein, showed a nonsignificant slowing of clinical progression compared with placebo and was generally well tolerated in patients with MSA.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is mitochondrial dysfunction in neurodegeneration!

New findings showed that treatment with ofatumumab lowered relapse risk compared with rituximab in patients with myelin oligodendrocyte glycoprotein antibody-associated disease.

Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discussed ongoing unmet needs in CIDP, diagnostic challenges, and emerging research efforts evaluating complement inhibition and biomarker-driven care approaches.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 22, 2026.

Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute discussed how structured cardiovascular rehabilitation may improve recovery outcomes, reduce mortality, and influence future Medicare coverage for poststroke care.

Mitzi Joi Williams, MD, is joined by movement disorder specialists Chantale Branson, MD, MSCR, FAAN, and Keisha Young, MD, PhD, to discuss the causes, evaluation, and management of tremor disorders.

A newly published analysis proposed a 4-point Tardive Dyskinesia Impact Scale (TDIS) threshold to interpret patient-reported improvement in patients living with tardive dyskinesia.

Wearable accelerometer metric 6M95C tracks Duchenne progression beyond walking loss, delivering effort‑independent, real‑world outcomes to strengthen late‑stage clinical trials.

Hybridopa improved MDS-UPDRS scores in a small phase 2a Parkinson disease trial, with phase 3 testing planned for 2026.

New phase 4 head-to-head data suggest Dysport may provide longer-lasting symptom control than Botox in adults with upper limb spasticity while maintaining comparable safety.

Anup Patel, MD, pediatric epileptologist at Nationwide Children’s Hospital and leader within the Pediatric Epilepsy Research Consortium, discusses evolving AI-driven initiatives, Lennox-Gastaut syndrome research priorities, and future directions in pediatric epilepsy care.

Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed emerging evidence supporting structured cardiovascular rehabilitation after stroke and ongoing efforts to expand access through potential Medicare policy changes.

The chief medical executive at Marcus Neuroscience Institute discussed the evolving role of AI, advanced imaging, and precision therapeutics in neurology presented at Baptist Health’s 2026 Brain & Spine Symposium. [WATCH TIME: 5 minutes]

The FDA's acceptance and priority review of levacetylleucine for ataxia-telangiectasia positions the therapy to potentially become the first approved treatment for the rare neurodegenerative disorder.

The registered nurse at the University of Miami and the president of the IOMSN discussed advice for younger colleagues, misconceptions about neurology nursing, and more. [WATCH TIME: 10 minutes]

Experts debate how to sequence new gMG therapies, manage seronegative and special populations, and close biomarker and access gaps.

The professor of psychiatry at the UCLA discussed postmortem findings suggesting that locus coeruleus neuron loss may be a more consistent feature of narcolepsy than hypocretin deficiency.

New RESTORE-FA results show DT-216P2 improved balance and fatigue within 4 weeks, with tolerable safety.

FDA Priority Review of asundexian marks a key regulatory milestone for factor XIa inhibition in secondary stroke prevention following positive phase 3 OCEANIC-STROKE results.

A retrospective study presented at AAN 2026 suggested that short-course methylprednisolone tapers may reduce headache severity and daily headache burden in patients with acute posttraumatic headache after mild traumatic brain injury.

From exercise and lifestyle medicine to neuromodulation and vagus nerve stimulation, Andrew Abdou, DO, discusses emerging approaches that may help stroke patients continue recovery beyond traditional timelines.

New findings suggest that patients with obstructive sleep apnea and excessive daytime sleepiness exhibit distinct endotypic traits that may influence disease severity and symptom expression.